Overview

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Status:
Active, not recruiting

Trial end date:
2022-05-30

Target enrollment:

Participant gender:

Summary

To evaluate the clinical efficacy (median event-free survival) of APL-1202 in combination with Epirubicin hydrochloride versus Epirubicin hydrochloride alone in intermediate and high-risk chemo-refractory non-muscle invasive bladder cancer (NMIBC) patients

Phase:

Phase 3

Details

Lead Sponsor:

Jiangsu Yahong Meditech Co., Ltd aka Asieris
Jiangsu Yahong Meditech Co.,Ltd.

Treatments:

Epirubicin